drug · antibody
ramucirumab
Phase 3updated 5mo agoby Eli Lilly and Co🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 18 investigational indications.
indications
indications
NSCLC
targets
Vascular endothelial growth factor receptor 2
all catalysts(0)
nothing on the calendar yet
Trials studying ramucirumab
- phase2Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
- phase2Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
- phase2Volrustomig Priming Regimens Exploratory Phase II Platform Study
- phase2Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- phase2A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
- phase2Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
- phase2CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
- phase2Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
News(2)
- 5 drugmakers chasing Merck and Moderna in the cancer vaccine raceFollowing their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…biospace · 19d ago
- BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readoutBioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.fiercebiotech · 22d ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that